ABBV vs DRMA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 02, 2026
ABBV
DRMA
Investment Advisor Scores
DRMA
AI Analyst Insights
Detailed Metrics Comparison
| Metric | ABBV | DRMA | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 16.3934 | 0 | Tie |
| PEG Ratio | 0.5421 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 10.2% | 0.0% | ABBV |
| Earnings Growth | 290.4% | 0.0% | ABBV |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 55.6/100 | 61.1/100 | DRMA |
| Profit Margin | 9.8% | 0.0% | ABBV |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
ABBV
NeutralMixed signals - no dominant trend phase, RSI 49
DRMA
MarkdownPrice below a falling SMA50 (slope -4.5%), weak momentum, RSI 40
Fundamentals Snapshot
| Metric | ABBV | DRMA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 16.0 | -0.8 |
| Trailing P/E | 74.5 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.0% |
| Gross Margin | 0.7% | — |
| Operating Margin | 0.4% | 0.0% |
| EPS | 3.51 | -4.20 |
| Dividend Yield | 0.03% | — |